NeuroD1 Gene Therapy

About NeuExcell Therapeutics

NeuExcell Therapeutics is a private, clinical-stage biotech based in Philadelphia, developing a transformative gene therapy platform for neural repair. Its core technology, the ATN platform, aims to regenerate functional neurons in vivo by reprogramming astrocytes, offering a potential disease-modifying approach for a broad range of neurological conditions. With three active clinical trials, over $25 million in disclosed funding, and a strong scientific foundation from founder Dr. Gong Chen, the company is positioned as a leader in the nascent field of direct neural reprogramming.

Therapeutic Areas